Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention

Antiviral Research

Volumn 97, Issue 3, 2013, Pages 334-346

  Zhang, Tao ^a   Zhang, Chi ^a   Agrahari, Vivek ^a   Murowchick, James B ^a   Oyler, Nathan A ^a   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

HIV AIDS microbicide; Mucoadhesive; PH sensitive; Spray drying; Tenofovir

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MICROSPHERE; TENOFOVIR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IN VITRO STUDY; INFLAMMATION; LACTOBACILLUS CRISPATUS; MUCOADHESION; PH; PRIORITY JOURNAL; PROTEIN SECRETION; SPERM; SPRAY DRYING; VAGINA EPITHELIUM; ZETA POTENTIAL;

ADENINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HIV INFECTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSPHERES; ORGANOPHOSPHONATES; PARTICLE SIZE;

LACTOBACILLUS CRISPATUS;

EID: 84873022888     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.019     Document Type: Article

References (50)

1. Agrahari V., Youan B.B. Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acid-based nanomedicine. AAPS PharmSciTech 2012, 13:202-210.
2. Chevanan N., Womac A.R., Bitra V.S., Igathinathane C., Yang Y.T., Miu P.I., Sokhansanj S. Bulk density and compaction behavior of knife mill chopped switchgrass, wheat straw, and corn stover. Bioresour. Technol. 2010, 101:207-214.
3. Christie R.J., Tadiello C.J., Chamberlain L.M., Grainger D.W. Optical properties and application of a reactive and bioreducible thiol-containing tetramethylrhodamine dimer. Bioconjug. Chem. 2009, 20:476-480.
4. Cilurzo F., Minghetti P., Selmin F., Casiraghi A., Montanari L. Polymethacrylate salts as new low-swellable mucoadhesive materials. J. Control. Release 2003, 88:43-53.
5. Cilurzo F., Selmin F., Minghetti P., Rimoldi I., Demartin F., Montanari L. Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam. Eur. J. Pharm. Sci. 2005, 24:355-361.
6. Clark M.R., Aliyar H.A., Lee C.W., Jay J.I., Gupta K.M., Watson K.M., Stewart R.J., Buckheit R.W., Kiser P.F. Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm 2011, 413:10-18.
7. das Neves J., Michiels J., Arien K.K., Vanham G., Amiji M., Bahia M.F., Sarmento B. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. 2011, 2012:1468-1484.
8. D'Cruz O.J., Erbeck D., Uckun F.M. A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol. Pathol. 2005, 33:465-476.
9. Degussa, 2011. EUDRAGIT L 100® and EUDRAGIT S 100 ® Specification and Test Methods.
10. Derringer G., Suich R. Simutaneous optimization of several response variables. J. Qual. Technol. 1980, 12:214.
11. FHI, 2011. VOICE HIV Prevention Trial Discontinues Tenofovir Gel Arm for Futility.
12. Fichorova R.N., Anderson D.J. Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol. Reprod. 1999, 60:508-514.
13. Fichorova R.N., Bajpai M., Chandra N., Hsiu J.G., Spangler M., Ratnam V., Doncel G.F. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 2004, 71:761-769.
14. Fichorova R.N., Zhou F., Ratnam V., Atanassova V., Jiang S., Strick N., Neurath A.R. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob. Agents Chemother. 2005, 49:323-335.
15. Gallagher, W., 2011. FTIR Analysis of Protein Structure. Available from:. (Accessed on 12/09/2011). http://www.chem.uwec.edu/chem455_S05/Pages/Manuals/FTIR_of_proteins.pdf.
16. Garg S., Goldman D., Krumme M., Rohan L.C., Smoot S., Friend D.R. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res. 2010, 88(Suppl 1):S19-S29.
17. Genc M.R., Vardhana S., Delaney M.L., Onderdonk A., Tuomala R., Norwitz E., Witkin S.S. Relationship between a toll-like receptor-4 gene polymorphism, bacterial vaginosis-related flora and vaginal cytokine responses in pregnant women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2004, 116:152-156.
18. Gonnissen Y., Remon J.P., Vervaet C. Effect of maltodextrin and superdisintegrant in directly compressible powder mixtures prepared via co-spray drying. Eur. J. Pharm. Biopharm. 2008, 68:277-282.
19. Gupta K.M., Barnes S.R., Tangaro R.A., Roberts M.C., Owen D.H., Katz D.F., Kiser P.F. Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J. Pharm. Sci. 2007, 96:670-681.
20. Ham A.S., Cost M.R., Sassi A.B., Dezzutti C.S., Rohan L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 2009, 26:502-511.
21. Hamdy S., Haddadi A., Ghotbi Z., Hung R.W., Lavasanifar A. Part I: targeted particles for cancer immunotherapy. Curr. Drug Deliv. 2011, 8:261-273.
22. Hung R.W., Hamdy S., Haddadi A., Ghotbi Z., Lavasanifar A. Part II: targeted particles for imaging of anticancer immune responses. Curr. Drug Deliv. 2011, 8:274-281.
23. Jankower L., Shipley W. Controlled Release Formulating Employing Resilient Microbeads 1989, US.
24. Johnson T.J., Gupta K.M., Fabian J., Albright T.H., Kiser P.F. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur. J. Pharm. Sci. 2010, 39:203-212.
25. Jorgenson J.H., Turnidge J.D., Washington J.A. Antibacterial susceptibility tests: dilution and disk diffusion methods. Manual of clinical microbiology 1999, ASM Press, Washington DC. 7 ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
26. Karim Q.A., Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and safety of tenofovir gel an antiretroviral microbicide for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
27. Lee W.A., He G.X., Eisenberg E., Cihlar T., Swaminathan S., Mulato A., Cundy K.C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 2005, 49:1898-1906.
28. Mahalingam A., Jay J.I., Langheinrich K., Shukair S., McRaven M.D., Rohan L.C., Herold B.C., Hope T.J., Kiser P.F. Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials 2011, 32:8343-8355.
29. Mbopi-Keou F.X., Trottier S., Omar R.F., Nkele N.N., Fokoua S., Mbu E.R., Domingo M.C., Giguere J.F., Piret J., Mwatha A., Masse B., Bergeron M.G. A randomized, double-blind, placebo-controlled phase II extended safety study of two invisible condom formulations in cameroonian women. Contraception 2010, 81:79-85.
30. McCormack S., Ramjee G., Kamali A., Rees H., Crook A.M., Gafos M., Jentsch U., Pool R., Chisembele M., Kapiga S., Mutemwa R., Vallely A., Palanee T., Sookrajh Y., Lacey C.J., Darbyshire J., Grosskurth H., Profy A., Nunn A., Hayes R., Weber J. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337.
31. Meng J., Sturgis T.F., Youan B.B. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci. 2011, 44:57-67.
32. Mohammadi G., Barzegar-Jalali M., Valizadeh H., Nazemiyeh H., Barzegar-Jalali A., Siahi Shadbad M.R., Adibkia K., Zare M. Reciprocal powered time model for release kinetic analysis of ibuprofen solid dispersions in oleaster powder, microcrystalline cellulose and crospovidone. J. Pharm. Pharm. Sci. 2010, 13:152-161.
33. Morrow K.M., Ruiz M.S. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008, 12:272-283.
34. Nekkanti V., Muniyappan T., Karatgi P., Hari M.S., Marella S., Pillai R. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. Drug Dev. Ind. Pharm. 2009, 35:1219-1229.
35. Newman A.W., Byrn S.R. Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov. Today 2003, 8:898-905.
36. Nielsen L.S., Schubert L., Hansen J. Bioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate. Eur. J. Pharm. Sci. 1998, 6:231-239.
37. Owen D.H., Katz D.F. A vaginal fluid simulant. Contraception 1999, 59:91-95.
38. Owen D.H., Katz D.F. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J. Androl. 2005, 26:459-469.
39. Patterson J.E., James M.B., Forster A.H., Lancaster R.W., Butler J.M., Rades T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 2005, 94:1998-2012.
40. Ren Y., Yu C., Meng K., Tang X. Influence of formulation and preparation process on ambroxol hydrochloride dry powder inhalation characteristics and aerosolization properties. Drug Dev. Ind. Pharm. 2008, 34:984-991.
41. Stevens-Simon C., Jamison J., McGregor J.A., Douglas J.M. Racial variation in vaginal pH among healthy sexually active adolescents. Sex Transm. Dis. 1994, 21:168-172.
42. Team C.P.I.S.A.S. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard(R) in South Africa. Contraception 2010, 82:563-571.
43. Tevi-Benissan C., Belec L., Levy M., Schneider-Fauveau V., Si Mohamed A., Hallouin M.C., Matta M., Gresenguet G. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diag. Lab. Immunol. 1997, 4:367-374.
44. UNAIDS Report on the global AIDS epidemic 2011.
45. UNAIDS/WHO, 2011. Global HIV/AIDS Response-Epidemic Update and Health Sector Progress Towards Universal Access. UNAIDS, Geneva, p. 229.
46. Wan L., Pooyan S., Hu P., Leibowitz M.J., Stein S., Sinko P.J. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm. Res. 2007, 24:2110-2119.
47. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. Engl. 2008, 47:9726-9729.
48. Whaley K.J., Hanes J., Shattock R., Cone R.A., Friend D.R. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res. 2010, 88(Suppl 1):S55-S66.
49. Zhang T., Sturgis T.F., Youan B.B. PH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur. J. Pharm. Biopharm. 2011, 79:526-536.
50. Zidan A.S., Spinks C., Fortunak J., Habib M., Khan M.A. Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J. 2010, 12:202-214.